Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/karger/benign-prostatic-hyperplasia-natural-evolution-versus-medical-FrREvpvDtj
References
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
- Publisher
- Karger
- Copyright
- © 1997 S. Karger AG, Basel
- ISSN
- 0302-2838
- eISSN
- 1873-7560
- DOI
- 10.1159/000480775
- Publisher site
- See Article on Publisher Site
Abstract
The epidemiology and natural evolution of benign prostatic hyperplasia(BPH) are important when considering the topic of natural evolution versusmedical treatment. The incidence of BPH increases with age; it is thought thatabout 75% of men over 50 years of age suffer from some symptoms commonlyassociated with BPH. There are also differences in the incidence of BPHbetween various racial and ethnic groups. For example, it is considerably lesscommon amongst Japanese men compared with Caucasians. Evidence fromprospective studies, retrospective studies and the placebo arms of randomised,controlled studies regarding the natural evolution of BPH suggests that astrategy of ‘watchful waiting’ may be considered as a treatment option as themajority of patients do not show a worsening of symptoms over time. However,the chance for improvement of symptoms and the degree of symptomimprovement has been shown to be higher with ai-blocker therapy than with‘watchful waiting’. As both symptoms and treatment have an impact on thepatient’s quality of life, there is now a strong case for involving the patient in
Journal
European Urology – Karger
Published: Jan 1, 2019
Keywords: Benign prostatic hyperplasia; α(1)-blockers; Quality of life; Epidemiology